Dr. Zvonić  is an established leader in business development, organizational leadership, product development, manufacturing, and technical operations in the cell and gene therapy (CGT) space. In his current role at Dark Horse Consulting Group, he is focused on business development and the strategic growth and market positioning of the Group. He also serves as the member of the Executive Leadership Team.

After earning his Doctorate in Cell and Molecular Biology Dr. Zvonić continued on to a post-doctoral position at the Pennington Biomedical Research Center where he contributed to the development of methodologies for the isolation and culture of human adipose stem cells (ASC) from several sources, and later utilized ASCs to develop a human in vitro model for circadian biology studies. He then transitioned onto a second post-doctoral role at Tulane University, where he directed the technology transfer and development of bone marrow-derived MSC manufacturing and analytical methods in the in-house GMP production facility.

In 2009, Dr. Zvonić joined Progenitor Cell Therapy (PCT), a leading CDMO in the CGT industry at the time, where he focused on client engagement and technology transfer, giving him a comprehensive understanding of the CGT market, drug development, manufacturing and commercialization requirements and strategies, as well as organizational growth and development strategies. Of note, Dr. Zvonić was a member of the teams that transferred early CGT assets that later became Yescarta, Zynteglo, Lyfgenia, and Teclera to their initial GMP homes outside academic environments.

In 2014, he joined Novartis Cell and Gene Therapy Unit, where he focused on the development and commercialization of Novartis CGT pipeline products, including Kymriah.

Dr. Zvonić returned to PCT in 2016, with a focus on driving the growth and development of PCT's clinical and commercial manufacturing business units as part of the acquisition and integration into Hitachi Chemical. This work included the transfer of know-how to the Japan flagship, integration and global harmonization of business and operational processes, and support of the establishment of the Japan-based operational capabilities.

Upon joining WindMIL Therapeutics in 2019, Dr. Zvonić lead the CMC development and manufacturing of WindMIL’s core technologies and pipeline products, while concurrently contributing to the organizational growth and development of this Johns Hopkins spin-out.

He joined DHCG in 2021 as a Principal consultant, leveraging his background as a cell and molecular biologist with a strong technical/scientific background in physiology, stem cell biology, and cell therapy CMC development. In 2022, Dr. Zvonić assumed his current role in order to support and drive the various ongoing organic and inorganic growth initiatives within the Group.